ArticleQuantitative imaging in medicine and surgery2026
Correlations of
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although small-size (T1, solid nodule with maximum diameter <3 cm) non-small cell lung cancer (NSCLC) is generally associated with a favorable prognosis, a notable subset of patients present with distant metastasis, a paradox that conventional staging fails to address. Fluorine-18-fluorodeoxyglucose ( Methods: This retrospective study enrolled 243 cases of pathologically confirmed T1 solid NSCLC, including 114 with and 129 without distant metastasis, who underwent Results: In the modeling cohort, high SUVpeak, SUVmean, SUVmax, MTV, TLG, and COV were significantly associated with distant metastasis (all P<0.05), except COV at SUV 1.0 (P=0.65). Multivariate regression confirmed COV at an SUV threshold of 2.0 (COV2.0) >0.33 as an independent risk factor [hazard ratio (HR) =3.03, P=0.01]. SII >641.68 was also identified as an independent inflammation-related risk factor (HR =2.84, P=0.003). COV2.0 was positively correlated with SII [odds ratio (OR) =4.55, P=0.03]. The co-high COV2.0/SII status was identified as an independent risk factor for metastasis (HR =5.08, P<0.001). In the independent validation cohort, the metastasis rate in the co-high COV2.0/SII group was 84.20% (16/19), significantly higher than the non-metastasis rate (15.80%, 3/19, P=0.043). The metastasis rate in the co-low COV2.0/SII group was only 17.90% (5/28, P<0.001). No clinicopathological features (age, gender, histological subtype, tumor diameter, smoking history) were associated with metastasis (all P>0.05). Conclusions: Enhanced glycolysis accompanied by a corresponding systemic immune response plays a critical role in T1 NSCLC metastasis. The combined assessment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.